top of page

Leadership Team

Jeffrey K. Allen, Ph.D.

Founder, President & CEO 


David H. Crean, Ph.D.

Chief Financial Officer


Peter Teriete, D. Phil.

Scientific Co-Founder

Dr. Jeff Allen has over 20 years of experience in biotechnology, analyzing complex biological problems and then combining new and existing technologies to create innovative solutions. Throughout his career at Beckman (Coulter), Gen-Probe (Hologic) and BD,  Jeff has utilized both technical and business skill sets to launch new molecular based systems. The same combination of skills sets is now being applied to help find a cure for cancer. Dr. Allen has assembled a team of exceptional scientists with expertise in many different areas and given them a single focus; identify and capture cancer stem cells, The Root Cause of Cancer.

David has +25 years buy- and sell-side expertise of M&A, partnering and investments within the life sciences and healthcare sectors working within strategic biopharmaceutical companies, private equity, investment banking and venture capital. David holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC. He holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science (MS) Degree in Oncology from the State University of New York at Buffalo. He earned a Bachelor of Science (BS) Degree in Biology/ Pre-Med from Canisius College. Additionally, Dr.Crean holds a Masters of Business Administration (MBA) Degree with a finance concentration from Pepperdine University Graziadio School of Management.

Peter is Director and Head of Lead Discovery at Ideaya Biosciences, where he leads a team identifying small molecule drugs against cancer targets, with a specific focus on synthetic lethality.

He received his D.Phil. in biophysics and biochemistry from the University of Oxford, United Kingdom, in 2004. Dr. Teriete was the lead scientist in solving the solution structure of the hyaluronan binding domain of the leukocyte homing receptor CD44. Dr. Teriete has published over 40 peer-reviewed research articles investigating relevant proteins for structure determination efforts, their role as bio-markers for prognosis in cancer, and as target to develop novel and potent therapeutics. Peter has been part of a team that brought multiple drugs to the clinic and has a deep understanding of the drug discovery and development process.

Scientific Advisory Board

Scientific & Medical Advisory Board

Ezra Cohen, MD

Associate Director, Professor of Medicine

UC San Diego Moores Cancer Center


Gregory Botta, MD, Ph.D.

Assistant Clinical Professor of Medicine

UC San Diego Moores Cancer Center


Sandip Patel, MD

Associate Professor of Medicine and

Co-Leader of Experimental Therapeutics 

UC San Diego Moores Cancer Center

Darren "Ben" Finlay, PhD

Research Associate Professor, NCI-Designated Cancer Center

Sanford Burnham Prebys Medical Discovery Institute

La Jolla, CA

Samuel K. Kassegne, Ph.D., PE

Associate Professor, Director of MEMS Research Lab
Department of Mechanical Engineering, SDSU

Leslie Crews, Ph.D.

Assistant Adjunct Professor

University of California, San Diego

Board of Directors

Bord of Directos

Jeffrey K. Allen, Ph.D.

Chairman of the Board


Peter Teriete, D. Phil.

Voting Member


Peter Coassin

Voting Member

bottom of page